Island Pharmaceuticals Ltd (ASX:ILA) has been granted a key patent for its lead drug candidate ISLA-101 by IP Australia, validating the company’s drug repurposing strategy to develop antiviral therapies with a key focus on mosquito-borne viral diseases.
The Australian patent grant entitled “Method of Viral Inhibition” was issued under Australian Patent No 2021205039 and relates to the method of treating or preventing flavivirus infections by administering ISLA-101.
The patent has an expiration date of April 16, 2034.
Patent reinforce investment
“This new patent adds to the growing intellectual property thicket that is being established around ISLA-101,” Island Pharmaceuticals chief executive officer Dr David Foster said.
“This Australian patent, together with the equivalent patents granted in other key markets, underpin the investment we are making in bringing forward ISLA-101 as a potential new approach to combating the world’s growing problem with dengue fever and other mosquito-borne viral diseases.”
READ: Island Pharmaceuticals readies for ISLA-101 trial for dengue fever
Island Pharmaceuticals has licensed the intellectual property (IP) portfolio for ISLA-101 from Monash University.
The company's robust IP portfolio now also includes patents in the US, Canada, Brazil and Singapore.